Literature DB >> 23771245

Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.

Eric J Kuo1, Ronald R Salem.   

Abstract

BACKGROUND: There is a paucity of evidence regarding incidence and predictors of survival in pancreatic neuroendocrine tumors (PNETs)≤2 cm in size.
METHODS: Patients having undergone resection for nonfunctioning PNETs were selected from the SEER database (1988-2009) and an institutional pathology database (1996-2012). PNETs≤2 cm were compared with PNETs>2 cm. Data were analyzed with χ2 tests, ANOVA, the Kaplan-Meier method, log rank tests, and Cox proportional hazard, and binary logistic regression.
RESULTS: The incidence of PNETs≤2 cm in the United States has increased by 710.4% over the last 22 years. Rates of extrapancreatic extension, nodal metastasis, and distant metastasis in PNETs≤2 cm in the SEER database were 17.9, 27.3, and 9.1%, respectively. The rate of nodal metastasis in our institutional series was 5.7%. Disease-specific survival at 5, 10, and 15 years for PNETs≤2 cm was 91.5, 84.0, and 76.8%. Decreased disease-specific survival was not associated with nodal metastasis, but rather with high grade [moderately differentiated, hazard ratio (HR) 37.2, 95% confidence interval (CI) 2.7-518.8; poorly differentiated, HR 94.2, 95% CI 4.9-1,794.4; reference, well differentiated], and minority race (Asian, HR 30.2, 95% CI 3.1-291.7; Black, HR 60.1, 95% CI 2.1-1,027.9; reference, White).
CONCLUSIONS: Pancreatic neuroendocrine tumors≤2 cm are increasingly common, and the most significant predictors of disease-specific survival are grade and race. The SEER database excludes PNETs considered to be benign, and rates of extrapancreatic extension, nodal metastasis, and distant metastasis are overestimated. Small size, however, does not preclude malignant behavior.

Entities:  

Mesh:

Year:  2013        PMID: 23771245     DOI: 10.1245/s10434-013-3005-7

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  55 in total

1.  A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors.

Authors:  Jessica E Maxwell; Scott K Sherman; Kristen M Stashek; Thomas M O'Dorisio; Andrew M Bellizzi; James R Howe
Journal:  Surgery       Date:  2014-11-11       Impact factor: 3.982

2.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

3.  Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States.

Authors:  Lauren Gratian; John Pura; Michaela Dinan; Sanziana Roman; Shelby Reed; Julie Ann Sosa
Journal:  Ann Surg Oncol       Date:  2014-05-20       Impact factor: 5.344

4.  Carbohydrate antigen 19-9 as a prognostic biomarker in pancreatic neuroendocrine tumors.

Authors:  Guopei Luo; Kaizhou Jin; He Cheng; Chen Liu; Meng Guo; Yu Lu; Chao Yang; Jinzhi Xu; Wenquan Wang; Heli Gao; Shirong Zhang; Jiang Long; Jin Xu; Quanxing Ni; Jie Chen; Xianjun Yu
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

Review 5.  [Surgical strategies for small sporadic neuroendocrine pancreatic tumors].

Authors:  K Holzer
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

6.  Robotic enucleations of pancreatic benign or low-grade malignant tumors: preliminary results and comparison with robotic demolitive resections.

Authors:  Ilenia Bartolini; Lapo Bencini; Marco Bernini; Marco Farsi; Massimo Calistri; Mario Annecchiarico; Luca Moraldi; Andrea Coratti
Journal:  Surg Endosc       Date:  2018-11-12       Impact factor: 4.584

7.  Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.

Authors:  Hussein A Assi; Sarbajit Mukherjee; Pamela L Kunz; Michael Machiorlatti; Sara Vesely; Vipul Pareek; Hassan Hatoum
Journal:  Oncologist       Date:  2019-10-02

8.  Predictive value of the Ki67 index for lymph node metastasis of small non-functioning pancreatic neuroendocrine neoplasms.

Authors:  Toshihiko Masui; Asahi Sato; Kenzo Nakano; Yuichiro Uchida; Akitada Yogo; Takayuki Anazawa; Kazuyuki Nagai; Yoshiya Kawaguchi; Kyoichi Takaori; Shinji Uemoto
Journal:  Surg Today       Date:  2019-03-05       Impact factor: 2.549

Review 9.  Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management.

Authors:  Jordan M Cloyd; George A Poultsides
Journal:  World J Gastroenterol       Date:  2015-08-28       Impact factor: 5.742

10.  Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study.

Authors:  Eran Sadot; Diane L Reidy-Lagunes; Laura H Tang; Richard Kinh Gian Do; Mithat Gonen; Michael I D'Angelica; Ronald P DeMatteo; T Peter Kingham; Bas Groot Koerkamp; Brian R Untch; Murray F Brennan; William R Jarnagin; Peter J Allen
Journal:  Ann Surg Oncol       Date:  2015-11-23       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.